Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

6.97
-0.2300-3.19%
Post-market: 6.95-0.0200-0.29%18:34 EDT
Volume:879.22K
Turnover:6.16M
Market Cap:713.95M
PE:-7.43
High:7.19
Open:7.16
Low:6.94
Close:7.20
52wk High:16.76
52wk Low:5.64
Shares:102.43M
Float Shares:78.77M
Volume Ratio:0.65
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9382
EPS(LYR):-1.0243
ROE:-24.75%
ROA:-15.19%
PB:1.55
PE(LYR):-6.80

Loading ...

Promising Outlook for Day One Biopharmaceuticals: Buy Rating Driven by Ojemda’s Market Potential

TIPRANKS
·
Apr 03

Day One Biopharm Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Mar 25

Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential

TIPRANKS
·
Mar 11

High Growth Tech Stocks In The US With Promising Potential

Simply Wall St.
·
Mar 11

Day One Biopharm Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 05

Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

Insider Monkey
·
Mar 05

Day One Biopharma’s Earnings Call Highlights Growth and Challenges

TIPRANKS
·
Feb 28

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Zacks
·
Feb 26

Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial

TIPRANKS
·
Feb 26

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Feb 26

Day One Biopharm Price Target Maintained With a $32.00/Share by Needham

Dow Jones
·
Feb 26

Oppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Feb 26

Day One Biopharmaceuticals Reports Strong 2024 Results

TIPRANKS
·
Feb 26

Promising Growth and Strategic Positioning Justify Buy Rating for Day One Biopharmaceuticals

TIPRANKS
·
Feb 26

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
Feb 26

Day One Biopharmaceuticals Reports 2024 Financial Results

TIPRANKS
·
Feb 26

Day One Biopharmaceutical Q4 GAAP EPS $(0.69) Misses $(0.36) Estimate, Sales $29.21M Beat $27.79M Estimate

Benzinga
·
Feb 26

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

GlobeNewswire
·
Feb 26

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Zacks
·
Feb 21

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 21